Nab-Paclitaxel in combination with Cisplatin Versus Docetaxel Plus Cisplatin as First-Line Therapy in Non-small Cell Lung Cancer

被引：20

作者：

Chen, Yi ^{[1
]}

Li, Jinyu ^{[2
]}

Chen, Shixue ^{[2
]}

Zhang, Yibao ^{[3
]}

Hu, Yi ^{[2
]}

Zhang, Guoqing ^{[2
]}

Yan, Xiang ^{[2
]}

Jiao, Shunchang ^{[2
]}

机构：

[1] Tsinghua Univ, Sch Clin Med, Beijing, Peoples R China

[2] Chinese Peoples Liberat Army Gen Hosp, Dept Med Oncol, Beijing, Peoples R China

[3] Peking Univ, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing,Dept Radiotherapy, Beijing, Peoples R China

来源：

SCIENTIFIC REPORTS | 2017年 / 7卷

基金：

中国国家自然科学基金; 北京市自然科学基金;

关键词：

PHASE-II TRIAL; CARBOPLATIN; CHEMOTHERAPY; GEMCITABINE; EFFICACY; SAFETY; NANOPARTICLE; CARCINOMA; RECURRENT; TAXOTERE;

D O I：

10.1038/s41598-017-11404-9

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Albumin-bound paclitaxel (nab-PC) and docetaxel both produced favorable efficacy and safety as first-line therapy in advanced non-small cell lung cancer (NSCLC). However, the comparison between nab-PC and docetaxel remained unclear until now. This retrospective study aimed to compare the efficacy and safety of nab-PC/cisplatin with docetaxel/cisplatin as first-line therapy in advanced NSCLC. 271 patients with advanced NSCLC, who received either nab-PC (55 patients) or docetaxel (216 patients) were reviewed from 2012 to 2016. The primary endpoint was objective overall response rate (ORR). The secondary endpoints were disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and safety profiles. Nab-PC presented a significantly higher ORR than docetaxel (47.3% vs 31.9%; P = 0.033). The difference of ORR was more significantly remarkable in patients with squamous histology (58.3% vs 29.0%; P = 0.007). Additionally, the DCR of nab-PC was significantly higher than docetaxel. Patients in nab-PC group had a trend toward improved PFS and OS compared with patients in docetaxel group, but this didn't reach statistical significance. Grade >= 3 neutropenia was less in nab-PC group, while Grade >= 3 anemia and thrombocytopenia were less in docetaxel group. Nab-PC/ cisplatin as first-line therapy, produced significantly higher efficacy and reduced neutropenia than docetaxel/cisplatin in advanced NSCLC.

引用

页数：7

共 39 条

[11] Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: A randomized, multicenter phase III trial [J].